Avecho Biotechnology Limited (AVEFF)
USD 0.0
(157.14%)
USD 0.0
(157.14%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 941.54 Thousand AUD | 2.27% |
| 2022 | 920.65 Thousand AUD | 29.79% |
| 2021 | 709.35 Thousand AUD | 1.31% |
| 2020 | 700.16 Thousand AUD | 25.9% |
| 2019 | 556.12 Thousand AUD | -38.35% |
| 2018 | 902.04 Thousand AUD | -50.87% |
| 2017 | 1.83 Million AUD | 7.57% |
| 2016 | 1.7 Million AUD | -6.0% |
| 2015 | 1.81 Million AUD | -3.04% |
| 2014 | 1.87 Million AUD | -14.36% |
| 2013 | 2.18 Million AUD | 44.93% |
| 2012 | 1.5 Million AUD | -58.44% |
| 2011 | 3.63 Million AUD | -75.4% |
| 2010 | 14.76 Million AUD | -15.04% |
| 2009 | 17.37 Million AUD | -1.48% |
| 2008 | 17.63 Million AUD | -53.29% |
| 2007 | 37.75 Million AUD | -0.69% |
| 2006 | 38.02 Million AUD | -2.35% |
| 2005 | 38.93 Million AUD | 4702.46% |
| 2004 | 810.73 Thousand AUD | 3127.69% |
| 2003 | 25.11 Thousand AUD | -17.24% |
| 2002 | 30.35 Thousand AUD | -46.21% |
| 2001 | 56.41 Thousand AUD | -69.54% |
| 2000 | 185.25 Thousand AUD | 156.71% |
| 1999 | 72.16 Thousand AUD | 117.59% |
| 1998 | 33.16 Thousand AUD | -54.87% |
| 1997 | 73.48 Thousand AUD | -98.74% |
| 1996 | 5.83 Million AUD | 4.6% |
| 1995 | 5.57 Million AUD | 1368.16% |
| 1994 | 380 Thousand AUD | -73.95% |
| 1993 | 1.45 Million AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.64 Million AUD | 75.04% |
| 2024 Q2 | 1.64 Million AUD | 0.0% |
| 2023 Q3 | 941.54 Thousand AUD | -45.49% |
| 2023 Q4 | 941.54 Thousand AUD | 0.0% |
| 2023 Q1 | 1.72 Million AUD | 87.61% |
| 2023 FY | 941.54 Thousand AUD | 2.27% |
| 2023 Q2 | 1.72 Million AUD | 0.0% |
| 2022 Q4 | 920.65 Thousand AUD | 0.0% |
| 2022 FY | 920.65 Thousand AUD | 29.79% |
| 2022 Q1 | 595.67 Thousand AUD | -16.03% |
| 2022 Q2 | 595.67 Thousand AUD | 0.0% |
| 2022 Q3 | 920.65 Thousand AUD | 54.56% |
| 2021 Q3 | 709.35 Thousand AUD | 8.94% |
| 2021 Q4 | 709.35 Thousand AUD | 0.0% |
| 2021 Q2 | 651.16 Thousand AUD | 0.0% |
| 2021 FY | 709.35 Thousand AUD | 1.31% |
| 2021 Q1 | 651.16 Thousand AUD | -7.0% |
| 2020 FY | 700.16 Thousand AUD | 25.9% |
| 2020 Q1 | 500.63 Thousand AUD | -9.98% |
| 2020 Q2 | 502.8 Thousand AUD | 0.43% |
| 2020 Q3 | 700.16 Thousand AUD | 39.25% |
| 2020 Q4 | 700.16 Thousand AUD | 0.0% |
| 2019 Q2 | 685.01 Thousand AUD | 0.3% |
| 2019 FY | 556.12 Thousand AUD | -38.35% |
| 2019 Q1 | 682.96 Thousand AUD | -24.29% |
| 2019 Q4 | 556.12 Thousand AUD | 0.0% |
| 2019 Q3 | 556.12 Thousand AUD | -18.82% |
| 2018 Q2 | 733.4 Thousand AUD | 0.0% |
| 2018 Q3 | 872.5 Thousand AUD | 18.97% |
| 2018 FY | 902.04 Thousand AUD | -50.87% |
| 2018 Q1 | 733.4 Thousand AUD | -60.06% |
| 2018 Q4 | 902.04 Thousand AUD | 3.39% |
| 2017 Q4 | 1.83 Million AUD | 7.16% |
| 2017 Q3 | 1.71 Million AUD | 17.19% |
| 2017 Q2 | 1.46 Million AUD | 0.0% |
| 2017 FY | 1.83 Million AUD | 7.57% |
| 2017 Q1 | 1.46 Million AUD | -14.34% |
| 2016 FY | 1.7 Million AUD | -6.0% |
| 2016 Q2 | 1.72 Million AUD | 0.0% |
| 2016 Q1 | 1.72 Million AUD | -5.12% |
| 2016 Q4 | 1.7 Million AUD | 2.61% |
| 2016 Q3 | 1.66 Million AUD | -3.44% |
| 2015 Q4 | 1.81 Million AUD | 1.97% |
| 2015 Q2 | 1.54 Million AUD | 0.0% |
| 2015 Q3 | 1.78 Million AUD | 15.2% |
| 2015 Q1 | 1.54 Million AUD | -17.46% |
| 2015 FY | 1.81 Million AUD | -3.04% |
| 2014 FY | 1.87 Million AUD | -14.36% |
| 2014 Q2 | 1.33 Million AUD | 0.0% |
| 2014 Q1 | 1.33 Million AUD | -38.87% |
| 2014 Q3 | 1.77 Million AUD | 32.98% |
| 2014 Q4 | 1.87 Million AUD | 5.34% |
| 2013 FY | 2.18 Million AUD | 44.93% |
| 2013 Q4 | 2.18 Million AUD | 3.16% |
| 2013 Q3 | 2.12 Million AUD | -5.15% |
| 2013 Q2 | 2.23 Million AUD | 0.0% |
| 2013 Q1 | 2.23 Million AUD | 48.11% |
| 2012 FY | 1.5 Million AUD | -58.44% |
| 2012 Q4 | 1.5 Million AUD | 0.0% |
| 2011 Q4 | 3.63 Million AUD | 0.0% |
| 2011 FY | 3.63 Million AUD | -75.4% |
| 2010 Q4 | 14.76 Million AUD | 0.0% |
| 2010 FY | 14.76 Million AUD | -15.04% |
| 2009 Q4 | 17.37 Million AUD | 0.0% |
| 2009 FY | 17.37 Million AUD | -1.48% |
| 2008 FY | 17.63 Million AUD | -53.29% |
| 2008 Q4 | 17.63 Million AUD | 0.0% |
| 2007 Q4 | 37.75 Million AUD | 0.0% |
| 2007 FY | 37.75 Million AUD | -0.69% |
| 2006 FY | 38.02 Million AUD | -2.35% |
| 2006 Q4 | 38.02 Million AUD | 0.0% |
| 2005 FY | 38.93 Million AUD | 4702.46% |
| 2005 Q4 | 38.93 Million AUD | 0.0% |
| 2004 Q4 | 810.73 Thousand AUD | 0.0% |
| 2004 FY | 810.73 Thousand AUD | 3127.69% |
| 2003 Q4 | 25.11 Thousand AUD | 0.0% |
| 2003 FY | 25.11 Thousand AUD | -17.24% |
| 2002 Q4 | 30.35 Thousand AUD | 0.0% |
| 2002 FY | 30.35 Thousand AUD | -46.21% |
| 2001 FY | 56.41 Thousand AUD | -69.54% |
| 2001 Q4 | 56.41 Thousand AUD | 0.0% |
| 2000 Q4 | 185.25 Thousand AUD | 0.0% |
| 2000 FY | 185.25 Thousand AUD | 156.71% |
| 1999 Q4 | 72.16 Thousand AUD | 0.0% |
| 1999 FY | 72.16 Thousand AUD | 117.59% |
| 1998 Q4 | 33.16 Thousand AUD | 0.0% |
| 1998 FY | 33.16 Thousand AUD | -54.87% |
| 1997 FY | 73.48 Thousand AUD | -98.74% |
| 1997 Q4 | 73.48 Thousand AUD | 0.0% |
| 1996 FY | 5.83 Million AUD | 4.6% |
| 1995 FY | 5.57 Million AUD | 1368.16% |
| 1994 FY | 380 Thousand AUD | -73.95% |
| 1993 FY | 1.45 Million AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Bioxytran, Inc. | 3.24 Million USD | 71.025% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 98.234% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -123.342% |
| SQZ Biotechnologies Company | 50.03 Million USD | 98.118% |
| Intellipharmaceutics International Inc. | 12 Million USD | 92.16% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 98.701% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 98.405% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 75.553% |
| Marizyme, Inc. | 26.67 Million USD | 96.47% |
| Genus plc | 485 Million USD | 99.806% |
| Pharming Group N.V. | 244.07 Million USD | 99.614% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 53.16% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 62.583% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 75.223% |
| ContraFect Corporation | 32.53 Million USD | 97.106% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 75.402% |
| IMV Inc. | 37.93 Million USD | 97.518% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 92.006% |
| ONE Bio Corp. | 27.49 Million USD | 96.576% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 98.784% |
| Mesoblast Limited | 188.44 Million USD | 99.5% |
| MultiCell Technologies, Inc. | 1617.67 USD | -58103.465% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 98.865% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.929% |
| Neon Bloom, Inc. | 1.22 Million USD | 23.216% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 81.704% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 90.174% |
| Biomind Labs Inc. | 1.49 Million USD | 37.173% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 89.587% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 94.884% |
| Skye Bioscience, Inc. | 14.07 Million USD | 93.309% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 34.335% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 83.885% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -562.613% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 52.479% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 90.053% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -368.158% |
| Accustem Sciences Inc. | 1.07 Million USD | 12.759% |
| EV Biologics, Inc. | 2.11 Million USD | 55.484% |
| Q BioMed Inc. | 8.13 Million USD | 88.423% |
| GB Sciences, Inc. | 5.41 Million USD | 82.621% |
| Alpha Cognition Inc. | 7.16 Million USD | 86.859% |
| CSL Limited | 18.62 Billion USD | 99.995% |
| Agentix Corp. | 2.51 Million USD | 62.497% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 99.207% |
| Enzolytics Inc. | 365.26 Million USD | 99.742% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 67.39 Million USD | 98.603% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -12.258% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 83.613% |
| argenx SE | 444.95 Million USD | 99.788% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 98.743% |
| HST Global, Inc. | 593.59 Thousand USD | -58.617% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 45.068% |
| Wesana Health Holdings Inc. | 1.25 Million USD | 25.227% |
| Halberd Corporation | 728.71 Thousand USD | -29.205% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 96.195% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 74.311% |
| Zenith Capital Corp. | 27.56 Thousand USD | -3315.213% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 92.09% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 74.787% |
| AVAX Technologies, Inc. | 3.99 Million USD | 76.425% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -38.292% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 65.278% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -294.521% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 7.86 Million USD | 88.022% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -1306.774% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 98.127% |
| Kadimastem Ltd | 3.5 Million USD | 73.136% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.9 Million USD | 94.08% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -102.613% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -3332.144% |
| LadRx Corporation | 2.2 Million USD | 57.213% |
| Cell Source, Inc. | 15.8 Million USD | 94.043% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -2006.542% |
| Regen BioPharma, Inc. | 5.45 Million USD | 82.748% |
| Regen BioPharma, Inc. | 5.45 Million USD | 82.748% |
| Affymax, Inc. | 8.87 Million USD | 89.386% |
| Mobile Lads Corp. | 1.31 Million USD | 28.318% |
| Itoco Inc. | 1.65 Million USD | 43.046% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 54.106% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 84.435% |
| International Stem Cell Corporation | 5.27 Million USD | 82.158% |
| CytoDyn Inc. | 127.89 Million USD | 99.264% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -2152.542% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 39.891% |
| Qrons Inc. | 1.48 Million USD | 36.755% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 91.476% |
| SYBLEU INC | 681.41 Thousand USD | -38.175% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -16.413% |
| Rebus Holdings, Inc. | 5.24 Million USD | 82.039% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 84.57% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -50.452% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 79.608% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 97.703% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 95.771% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 53.513% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 82.812% |
| Neutra Corp. | 973.52 Thousand USD | 3.286% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 96.755% |
| PureTech Health plc | 125.58 Million USD | 99.25% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 74.94% |
| IXICO plc | 1.9 Million USD | 50.453% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 95.414% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.089% |
| CSL Limited | 18.62 Billion USD | 99.995% |
| Cellectis S.A. | 249.36 Million USD | 99.622% |